Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials

Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials

Background: Tanezumab is a nerve growth factor monoclonal antibody that may regulate pain in hip or knee osteoarthritis (OA). This meta-analysis was performed to evaluate the efficacy and safety of low and moderate doses of tanezumab in treating hip or knee OA. Methods: PubMed, EMBASE, the Cochrane...

Full description

Bibliographic Details
Main Authors: Di Zhao, Ming-hui Luo, Jian-ke Pan, Ling-feng Zeng, Gui-hong Liang, Yan-hong Han, Jun Liu, Wei-yi Yang
Format: Article
Language:English
Published: SAGE Publishing 2022-01-01
Series:Therapeutic Advances in Musculoskeletal Disease
Online Access:https://doi.org/10.1177/1759720X211067639

Internet

https://doi.org/10.1177/1759720X211067639

Similar Items